3 results
Primary:To demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks compared to remaining on ABC/DTG/3TC (or DTG and an approved dual-NRTI scheme) over 48 weeks.Secondary:To…
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…
Primary objective: To investigate the clinical effectiveness of the novel anal insert (Navina* Fecal Incontinence Insert) in ambulatory patients with faecal incontinence in comparison to care as usual (e.g. incontinence pads)Secondary objectives:1.…